Physician profile
Hugh E Thompson
NPI 1275610578
$3,217.77
in general payments reported to CMS, 2019-2025
39 companies · $551 in 2025
The $551 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,082 · 2020: $209 · 2021: $121 · 2022: $240 · 2023: $501 · 2024: $514 · 2025: $551.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,566.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,566.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $376.92 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $370.27 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $344.79 | 2019-2025 | |
| Amgen INC. | $207.90 | 2019-2025 | Repatha, Evenity, Prolia |
| Glaxosmithkline, LLC. | $173.00 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boston Scientific Corporation | $157.82 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $153.77 | 2019-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $139.88 | 2019-2024 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $128.92 | 2019-2025 | Jardiance |
| Abbvie INC. | $99.13 | 2022-2024 | Ubrelvy, Qulipta, Vraylar |
| Janssen Pharmaceuticals, INC | $91.21 | 2019-2023 | Xarelto |
| Exact Sciences Corporation | $85.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $78.88 | 2019-2021 | |
| Esperion Therapeutics, INC. | $66.91 | 2021-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $64.52 | 2019-2023 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hugh Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.